Back to Search Start Over

Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin.

Authors :
UCL - SSS/IONS - Institute of NeuroScience
UCL - (MGD) Service de neurologie
Amarenco, Pierre
Denison, Hans
Evans, Scott R
Himmelmann, Anders
James, Stefan
Knutsson, Mikael
Ladenvall, Per
Molina, Carlos A
Wang, Yongjun
Johnston, S Claiborne
THALES Steering Committee and Investigators*
Vandermeeren, Yves
UCL - SSS/IONS - Institute of NeuroScience
UCL - (MGD) Service de neurologie
Amarenco, Pierre
Denison, Hans
Evans, Scott R
Himmelmann, Anders
James, Stefan
Knutsson, Mikael
Ladenvall, Per
Molina, Carlos A
Wang, Yongjun
Johnston, S Claiborne
THALES Steering Committee and Investigators*
Vandermeeren, Yves
Source :
Stroke, Vol. 51, no. 12, p. 3504-3513 (2020)
Publication Year :
2020

Abstract

Among patients with a transient ischemic attack or minor ischemic strokes, those with ipsilateral atherosclerotic stenosis of cervicocranial vasculature have the highest risk of recurrent vascular events. In the double-blind THALES (The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death) trial, we randomized patients with a noncardioembolic, nonsevere ischemic stroke, or high-risk transient ischemic attack to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30) within 24 hours of symptom onset. The present paper reports a prespecified analysis in patients with and without ipsilateral, potentially causal atherosclerotic stenosis ≥30% of cervicocranial vasculature. The primary end point was time to the occurrence of stroke or death within 30 days. Of 11 016 randomized patients, 2351 (21.3%) patients had an ipsilateral atherosclerotic stenosis. After 30 days, a primary end point occurred in 92/1136 (8.1%) patients with ipsilateral stenosis randomized to ticagrelor and in 132/1215 (10.9%) randomized to placebo (hazard ratio 0.73 [95% CI, 0.56-0.96], =0.023) resulting in a number needed to treat of 34 (95% CI, 19-171). In patients without ipsilateral stenosis, the corresponding event rate was 211/4387 (4.8%) and 230/4278 (5.4%), respectively (hazard ratio, 0.89 [95% CI, 0.74-1.08]; =0.23, =0.245). Severe bleeding occurred in 4 (0.4%) and 3 (0.2%) patients with ipsilateral atherosclerotic stenosis on ticagrelor and on placebo, respectively (=NS), and in 24 (0.5%) and 4 (0.1%), respectively, in 8665 patients without ipsilateral stenosis (hazard ratio=5.87 [95% CI, 2.04-16.9], =0.001). In this exploratory analysis comparing ticagrelor added to aspirin to aspirin alone, we found no treatment by ipsilateral atherosclerosis stenosis subgroup interaction but did identify a higher absolute risk and

Details

Database :
OAIster
Journal :
Stroke, Vol. 51, no. 12, p. 3504-3513 (2020)
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1288285008
Document Type :
Electronic Resource